When a drug stock ends years of 50% Y/Y earnings per share growth in the last five years, the stock will naturally drop. For Gilead Sciences (GILD), the downtrend is severe: the stock is down around 35% in the last year.
Quarterly results
Gilead’s quarterly results do not give investors any confidence. Not only did executives give themselves …View the full post at: Gilead Sciences (GILD) Value Trap …
Related Articles:
Jack Dorsey Just Bought A Chunk of Twitter (TWTR) Stock
Finding Edge in Goldman Sachs (GS) Options
Apple (AAPL) Video Will Humiliate the Skeptics Again
Coke (KO) and Pepsi Are Investing Heavily In Healthy Beverages